RecruitingPhase 2NCT01356290
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Studying Atypical teratoid rhabdoid tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Medical University of Vienna
- Principal Investigator
- Andreas Peyrl, MDMedical University of Vienna
- Intervention
- Bevacizumab(drug)
- Enrollment
- 232 enrolled
- Eligibility
- 19 years · All sexes
- Timeline
- 2014 – 2030
Study locations (22)
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
- Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
- Dell Children's Medical Group SFC-HEM/ONC, Austin, Texas, United States
- Medical University of Graz, Graz, Austria
- Medical University of Innsbruck, Innsbruck, Austria
- Kepler Universitätsklinikum Med Campus IV, Linz, Austria
- Salzburger Universitätsklinikum, Salzburg, Austria
- Medical University of Vienna, Vienna, Austria
- University Hospital Brno, Brno, Czechia
- Motol University Hospital Prague, Prague, Czechia
- University hospital Rigshospitalet, Copenhagen, Denmark
- Centre Oscar Lambret, Lille, France
- Centre Léon Bérard, Lyon, France
- Onkologisk-hematologisk seksjon Barneklinikken Haukeland universitetssjukehus, Bergen, Norway
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01356290 on ClinicalTrials.govOther trials for Atypical teratoid rhabdoid tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06465199Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasMilton S. Hershey Medical Center
- RECRUITINGEARLY PHASE1NCT07017816A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.Children's National Research Institute
- RECRUITINGPHASE2NCT06622941Study to ONO-4538 in Patients With Rhabdoid TumorOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06193759Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)Children's National Research Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsSusan Chi, MD
- RECRUITINGPHASE1NCT05835687Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS TumorsSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05286801Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT06853080Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid TumorsTaipei Medical University